Valion Bio (VBIO) Profit After Tax (2021 - 2025)

Valion Bio has reported Profit After Tax for 5 years, with the latest figure at -$2.6 million in Q3 2025.

• On a quarterly basis, Profit After Tax fell 81.41% year-over-year to -$2.6 million in Q3 2025; TTM through Sep 2025 was -$7.5 million, a 17.26% decrease from a year earlier, with the FY2024 full-year figure at -$5.7 million, up 30.86% from the prior year.
• Profit After Tax was -$2.6 million for Q3 2025 at Valion Bio, down from -$1.9 million in the prior quarter.
• The five-year high for Profit After Tax was -$1.1 million in Q2 2021, with the low at -$3.7 million in Q4 2021.
• Average Profit After Tax over 5 years is -$2.0 million, with a median of -$2.1 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2024: Profit After Tax slumped 175.87% in 2022, then jumped 40.42% in 2024.
• Over 5 years, Profit After Tax stood at -$3.7 million in 2021, then jumped by 39.37% to -$2.3 million in 2022, then climbed by 0.66% to -$2.2 million in 2023, then soared by 33.13% to -$1.5 million in 2024, then plunged by 73.07% to -$2.6 million in 2025.
• The last three Profit After Tax figures came in at -$2.6 million (Q3 2025), -$1.9 million (Q2 2025), and -$1.5 million (Q1 2025), per Business Quant data.